Skip to main content
. 2022 Aug 2;16:2463–2478. doi: 10.2147/DDDT.S370574

Figure 7.

Figure 7

(A) The Mpro enzyme in the dimer form with co-crystallized ligands, (B) AT-7519 (PDB:7AGA32) and (C) Pelitinib (PDB:7AXM32) at the dimer interface indicates opportunities for allosteric modulation. For clarity, superimposition on the dimer form of Mpro (PDB:7CAM79) was performed to demonstrate binding onto the dimerization site.